BRCA1 and neoplasm: TCGA dataset set also provided evidence that BRCA1-mutated tumors have higher levels of tumor-specific neoantigens, recruiting a prominent lymphocytic infiltrate and leading to a more robust higher T cell response than BRCA1-wild-type TNBCs [133], supporting a rational strategy for immunotherapy in combination with DNA repair targeted agents in BRCA1-associated TNBC.